{
  "pmcid": "9351589",
  "sha256": "c23ffcfe10bcae92efda29d2e4a415f9424f36a34e45e6ae164ec68d26479a73",
  "timestamp_utc": "2025-11-09T16:21:13.356795+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.95245283018868,
    "reading_ease": 45.67669085631351,
    "word_count": 265
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This phase II trial randomized patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with K RAS WT resected colorectal liver metastases (CRLM)"
      },
      "Intervention": {
        "score": 2,
        "evidence": "adjuvant HAI FUDR + SYS FOLFIRI +/âˆ’ Pmab"
      },
      "Objective": {
        "score": 1,
        "evidence": "The purpose was to determine whether adding Pmab versus no Pmab to an adjuvant regimen of HAI of floxuridine (FUDR) plus systemic (SYS) leucovorin, fluorouracil, and irinotecan (FOLFIRI) improves 15-month recurrence-free survival (RFS) for patients with RAS wild-type (WT) colorectal cancer."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "15-month recurrence-free survival (RFS)"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "randomized patients"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Seventy-five patients were randomized."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Twenty-five (69%; 95% CI, 53 to 82) patients in the Pmab arm versus 18 (47%; 95% CI, 32 to 63) patients in the arm without Pmab were alive and recurrence-free at 15 months."
      },
      "Harms": {
        "score": 1,
        "evidence": "Patient characteristics and toxicity were not different in the two arms, except for rash in +Pmab arm."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "NCT01312857"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}